Developer docs
API playgroundTry for free, no card

Search company profiles

Erbi Biosystems

Full company profile

uuid0002v9y

Namestring
Erbi Biosystems
Websiteurl
erbi-bio.com
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStoneham, United States
HQ citystring
Stoneham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
microfluidic bioreactors, cell culture systems, bioprocess instrumentation, cell therapy manufacturing, lab-scale bioreactors
Industry1 code
PRIMARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Bioprocess Instrumentation
Social media profiles1 record
Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Erbi Biosystems develops and manufactures the Breez Bioreactor, a small-scale cell culture platform that combines continuous media addition with online sensing for advanced cell therapy applications. The system targets developers of CAR-T therapies, stem cell therapies, and other cell-based treatments that require precise, controlled culture conditions. Founded in 2015 and headquartered in Woburn, United States, the company operates as a transformative microfluidic bioprocess instrumentation provider serving the cell therapy industry.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Erbi Biosystems offers a single unified product — the Breez Bioreactor — which is an advanced small-scale cell culture system. The system is designed for cell therapy applications and features continuous media addition and integrated online sensing for real-time monitoring. The company is developing new cell therapy applications leveraging this platform technology.

Product and service1 record
1Breez Bioreactor
CategoryCell Culture Bioreactors
Description

A small-scale cell culture system with continuous media addition and online sensing designed for cell therapy applications including CAR-T and stem cell therapy development. Intended for biotech and pharmaceutical researchers and manufacturers developing cell-based therapies.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

PBS Biotech makes single-use, high-cell-density bioreactors specifically designed for cell therapy and viral vector manufacturing. Directly comparable to Erbi Breez as both serve cell therapy developers needing small-scale, controlled cell culture systems with monitoring capabilities.

TypeBroad incumbent
Description

Sartorius is a leading supplier of bioprocess equipment, including the ambr line of miniature stirred-tank bioreactors used widely in cell line development and process optimization. Overlaps with Erbi's small-scale bioreactor focus for cell therapy, but Sartorius operates across a much broader bioprocess portfolio.

TypeBroad incumbent
Description

Cytiva (formerly GE Healthcare Life Sciences) provides the Xuri cell expansion system and other bioreactor/wave platforms used in cell therapy manufacturing. Overlaps with Erbi on cell therapy culture hardware but competes as a much larger full-line bioprocess supplier.

TypeBroad incumbent
Description

Eppendorf offers the DASbox and DASGIP parallel bioreactor systems widely used for small-scale, sensor-rich process development. Comparable to Erbi in miniaturized bioreactor form factors with online monitoring, but serving broader bioprocess customers beyond cell therapy.

TypeBroad incumbent
Description

Thermo Fisher acquired Finesse Solutions (smart bioreactor sensors and control platforms) and sells a range of bioprocess instruments including the HyPerforma GelliArm system for cell therapy. It is a broad incumbent covering cell therapy manufacturing adjacent to Erbi's niche.

6Applikon Biotechnology
TypeDirect peer
Description

Applikon (now part of Getinge) is a specialist bioreactor manufacturer offering my-Control and similar small-scale systems with advanced sensor integration. Direct overlap with the Breez in delivering controlled, monitored cell culture at small scale.

7Corning Life Sciences
TypeBroad incumbent
Description

Corning supplies single-use bioreactors, culture vessels, and cell expansion platforms (e.g., Corning CELLSTACK, closed-system cell culture) used widely in cell therapy workflows. Comparable adjacent infrastructure to Erbi's Breez in cell therapy manufacturing.

TypeDirect peer
Description

Finesse Solutions (now part of Thermo Fisher) built smart sensors, controllers, and bioreactor platforms specifically for cell therapy process monitoring. Direct peer to Erbi on the online sensing and process control layer of small-scale cell culture.

TypeBroad incumbent
Description

Miltenyi offers the Prodigy and other cell processing/instrumentation systems for cell therapy manufacturing. Overlaps with Erbi as a closed-system, process-controlled cell therapy equipment vendor, with a much broader product portfolio spanning cell separation to bioprocessing.

TypeEmerging player
Description

Cellexus develops single-use bioreactor systems aimed at cell and gene therapy applications. Closely comparable emerging player focusing on small-scale, automated cell culture technology similar to Erbi's Breez platform.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Erbi Biosystems

Bioprocess Instrumentationerbi-bio.com

Erbi Biosystems firmographics

Firmographics
Name
Erbi Biosystems
Website
https://erbi-bio.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Erbi Biosystems industry classification

Industry
Product category
Bioprocess Instrumentation
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • Microfluidic bioreactors
  • Cell culture systems
  • Bioprocess instrumentation
  • Cell therapy manufacturing
  • Lab-scale bioreactors

Where Erbi Biosystems is headquartered

Location

Headquarters

HQ city
Stoneham
HQ country
United States
HQ region
North America

Markets served

Erbi Biosystems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Erbi Biosystems product offering

Product offering

Core offering

Erbi Biosystems develops and manufactures the Breez Bioreactor, a small-scale cell culture platform that combines continuous media addition with online sensing for advanced cell therapy applications. The system targets developers of CAR-T therapies, stem cell therapies, and other cell-based treatments that require precise, controlled culture conditions. Founded in 2015 and headquartered in Woburn, United States, the company operates as a transformative microfluidic bioprocess instrumentation provider serving the cell therapy industry.

Product overview

Erbi Biosystems offers a single unified product — the Breez Bioreactor — which is an advanced small-scale cell culture system. The system is designed for cell therapy applications and features continuous media addition and integrated online sensing for real-time monitoring. The company is developing new cell therapy applications leveraging this platform technology.

Differentiator

Problem solved

Functional benefit

Products and services

  • Breez Bioreactor A small-scale cell culture system with continuous media addition and online sensing designed for cell therapy applications including CAR-T and stem cell therapy development. Intended for biotech and pharmaceutical researchers and manufacturers developing cell-based therapies.

Companies that use Erbi Biosystems

Customer profile

Segments1 record

Ideal customer profiles1 record

Erbi Biosystems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Erbi Biosystems partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Erbi Biosystems competitors and assessment

Company assessment

Direct peers

  • PBS Biotech: PBS Biotech makes single-use, high-cell-density bioreactors specifically designed for cell therapy and viral vector manufacturing. Directly comparable to Erbi Breez as both serve cell therapy developers needing small-scale, controlled cell culture systems with monitoring capabilities.
  • Applikon Biotechnology: Applikon (now part of Getinge) is a specialist bioreactor manufacturer offering my-Control and similar small-scale systems with advanced sensor integration. Direct overlap with the Breez in delivering controlled, monitored cell culture at small scale.
  • Finesse Solutions: Finesse Solutions (now part of Thermo Fisher) built smart sensors, controllers, and bioreactor platforms specifically for cell therapy process monitoring. Direct peer to Erbi on the online sensing and process control layer of small-scale cell culture.

Broad incumbents

  • Sartorius AG: Sartorius is a leading supplier of bioprocess equipment, including the ambr line of miniature stirred-tank bioreactors used widely in cell line development and process optimization. Overlaps with Erbi's small-scale bioreactor focus for cell therapy, but Sartorius operates across a much broader bioprocess portfolio.
  • Cytiva: Cytiva (formerly GE Healthcare Life Sciences) provides the Xuri cell expansion system and other bioreactor/wave platforms used in cell therapy manufacturing. Overlaps with Erbi on cell therapy culture hardware but competes as a much larger full-line bioprocess supplier.
  • Eppendorf: Eppendorf offers the DASbox and DASGIP parallel bioreactor systems widely used for small-scale, sensor-rich process development. Comparable to Erbi in miniaturized bioreactor form factors with online monitoring, but serving broader bioprocess customers beyond cell therapy.
  • Thermo Fisher Scientific: Thermo Fisher acquired Finesse Solutions (smart bioreactor sensors and control platforms) and sells a range of bioprocess instruments including the HyPerforma GelliArm system for cell therapy. It is a broad incumbent covering cell therapy manufacturing adjacent to Erbi's niche.
  • Corning Life Sciences: Corning supplies single-use bioreactors, culture vessels, and cell expansion platforms (e.g., Corning CELLSTACK, closed-system cell culture) used widely in cell therapy workflows. Comparable adjacent infrastructure to Erbi's Breez in cell therapy manufacturing.
  • Miltenyi Biotec: Miltenyi offers the Prodigy and other cell processing/instrumentation systems for cell therapy manufacturing. Overlaps with Erbi as a closed-system, process-controlled cell therapy equipment vendor, with a much broader product portfolio spanning cell separation to bioprocessing.

Emerging players

  • Cellexus: Cellexus develops single-use bioreactor systems aimed at cell and gene therapy applications. Closely comparable emerging player focusing on small-scale, automated cell culture technology similar to Erbi's Breez platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Erbi Biosystems social profiles

Digital presence

Erbi Biosystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Erbi Biosystems leadership team

Management profile

Number of profiles

Profiles5 records

Erbi Biosystems funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Erbi Biosystems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Erbi Biosystems

What does Erbi Biosystems do?

Erbi Biosystems develops and manufactures the Breez Bioreactor, a small-scale cell culture platform that combines continuous media addition with online sensing for advanced cell therapy applications. The system targets developers of CAR-T therapies, stem cell therapies, and other cell-based treatments that require precise, controlled culture conditions. Founded in 2015 and headquartered in Woburn, United States, the company operates as a transformative microfluidic bioprocess instrumentation provider serving the cell therapy industry.

Is Erbi Biosystems a public or private company?

Erbi Biosystems is a private company. It is classified as venture growth investor backed and is currently operating.

When was Erbi Biosystems founded?

Erbi Biosystems was founded in 2016. It employs 11 to 50 people.

Where is Erbi Biosystems based?

Erbi Biosystems is headquartered in Stoneham, United States, in the North America region.

Who are Erbi Biosystems's main competitors?

Direct peers on record are PBS Biotech, Applikon Biotechnology and Finesse Solutions. Broad incumbents are Sartorius AG, Cytiva, Eppendorf, Thermo Fisher Scientific, Corning Life Sciences and Miltenyi Biotec. Cellexus is listed as an emerging player.

Does Erbi Biosystems have an API?

No public API is recorded for Erbi Biosystems.

What industry is Erbi Biosystems in?

Erbi Biosystems's product category is Bioprocess Instrumentation. Its primary akta.pro industry code is HLAAAJAE, Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES). Its NAICS code is 541714 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewswireMilliporeSigma Gains Leading Perfusion Micro-Bioreactor with Erbi Biosystems AcquisitionMilliporeSigma acquired Massachusetts-based Erbi Biosystems, which develops the Breez micro-bioreactor platform. The deal expands MilliporeSigma's bioreactor portfolio from 2ml to 2000L and adds expertise in monoclonal antibody process development. Financial terms were not disclosed.PR NewswireMilliporeSigma Gains Leading Perfusion Micro-Bioreactor with Erbi Biosystems AcquisitionMilliporeSigma acquired Massachusetts-based Erbi Biosystems, a developer of the 2 ml micro-bioreactor platform Breez, to expand its therapeutic protein upstream portfolio. The deal enables scalable perfusion bioreactor processes from 2 ml to 2000 L and adds expertise in monoclonal antibody process development. Financial terms were not disclosed.ContractpharmaMilliporeSigma Acquires Erbi BiosystemsMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, has acquired Massachusetts-based Erbi Biosystems to integrate its Breez micro-bioreactor technology into its upstream portfolio. The acquisition aims to strengthen scalable cell-based perfusion processes for therapeutic proteins and cell therapies, although financial terms were not disclosed. This move supports Merck KGaA's strategy to accelerate innovation and increase group sales to approximately €25 billion by 2025.BioSpaceErbi Biosystems Strengthens Executive Leadership Team with Appointment of Chief Scientific OfficerErbi Biosystems appointed Brad Hamilton as Chief Scientific Officer, effective immediately. He previously served as Chief Scientific Officer at GoodCell and Chief Technology Officer at ReproCELL. The company expects to maintain its 2021 headcount growth in 2022.PR NewswireErbi Biosystems Strengthens Executive Leadership Team with Appointment of Chief Scientific OfficerErbi Biosystems announced the appointment of Brad Hamilton as Chief Scientific Officer, effective immediately, to lead the company's scientific research efforts. Hamilton brings over 25 years of scientific leadership experience, including previous roles as CSO at GoodCell and CTO at multinational stem cell company ReproCELL. The company, which doubled its headcount in 2021, expects to maintain this growth trajectory while developing GMP-compliant systems for clinical cell therapy manufacturing.Pulse 2.0Erbi Biosystems Raises $4 Million In FundingErbi Biosystems raised $4 million in funding to expand operations and develop extensions for its Breez perfusion bioreactor. The company expects to double its staff again in 2022, with revenue from Breez customers in the US, Europe, and Asia fueling growth.dlvr.itErbi Biosystems Raises $4 Million In FundingErbi Biosystems has raised $4 million in funding to expand operations and develop extensions for its Breez perfusion bioreactor product. The capital will support the company's growth in cell therapy applications, following a recent doubling of staff and relocation to a larger facility near Cambridge.PR NewswireErbi Biosystems Raises $4M to Provide Small-Scale Perfusion Bioreactors for Development and Manufacture of Cell TherapiesErbi Biosystems has closed a private funding round of $4 million to expand operations and enhance its Breez perfusion bioreactor product for cell therapy applications. The financing will support the company's growth strategy, including scaling manufacturing capabilities and accelerating technology development projects in the US, Europe, and Asia. This investment aims to meet growing demand for small-scale, automated cell culture systems used in process development and GMP manufacturing.FinSMEsErbi Biosystems Raises $3.8M in FundingErbi Biosystems, a Woburn, MA-based microfluidic bioprocess instrumentation company, closed a $3.8M funding round led by Jaguar Biotech. The funds will expand manufacturing, sales, and support of its 2mL TruePerfusion Breez bioreactor, and further develop its technology platform and product pipeline.PR NewswireErbi Biosystems raises $3.8M to expand their platform of microfluidic bioprocess and bioreactor equipment, which enables ultra-high cell density and continuous processingErbi Biosystems, a microfluidic bioprocess instrumentation company based in Woburn, Massachusetts, announced the closing of a $3.8M financing round led by Jaguar Biotech, bringing total investment received to nearly $4M. The funding will be used to expand manufacturing, sales, and support of the existing 2mL TruePerfusion Breez bioreactor while also funding further development of the technology platform and product pipeline, including cell and gene therapy applications. The company recently shipped three complete systems to a global biopharma customer for media development capabilities.